Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the
Company), focused on developing and commercializing medicines to
improve the survival and quality of life of cancer patients, today
reported financial results for the quarter ended June 30, 2018 and
provided an overview of certain corporate developments.
“During the second quarter of 2018, we’ve been actively
preparing for the commercialization of duvelisib, our
first-in-class, oral dual inhibitor of phosphoinositide 3-kinase
(PI3K)-delta and PI3K-gamma for the treatment of patients with
relapsed or refractory chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL) or follicular lymphoma (FL),” said
Robert Forrester, President and Chief Executive Officer of Verastem
Oncology. “In advance of our target action date of October 5, 2018,
we have been building our U.S. sales force and commercial
capabilities in preparation for a potential product launch of
duvelisib in the U.S. in 2018. On the financial front, we have
significantly strengthened our balance sheet, ending June 30, 2018
with $168.7 million in cash and cash equivalents.”
Second Quarter 2018 and Recent Highlights:
Corporate and Financial
- Duvelisib NDA accepted by FDA with
priority review – In April 2018, Verastem Oncology announced
that the U.S. Food and Drug Administration (FDA) accepted the
duvelisib New Drug Application (NDA) for filing with Priority
Review, with a target action date of October 5, 2018. In the
accepted NDA, the Company is seeking full approval for duvelisib,
its first-in-class investigational oral dual inhibitor of
PI3K-delta and PI3K-gamma, for the treatment of relapsed or
refractory CLL/SLL and accelerated approval for the treatment of
relapsed or refractory FL. The duvelisib NDA is supported by
clinical data from the randomized Phase 3 DUO™ study evaluating
duvelisib as a monotherapy in patients with relapsed or refractory
CLL/SLL, as well as the Phase 2 DYNAMO™ study evaluating patients
with iNHL that are double-refractory to both rituximab and
chemotherapy or radioimmunotherapy. Both DUO and DYNAMO achieved
their primary endpoints.
- Hosted Analyst and Investor Day
highlighting commercial potential of duvelisib – In
early May 2018, Verastem Oncology hosted an Analyst and Investor
Day in New York City titled, “Duvelisib: Harnessing the Power of
Dual PI3K Inhibition.” Key opinion leaders in the hematologic
oncology field including Dr. Lori Kunkel, Former Chief Medical
Officer, Pharmacyclics, Dr. Jennifer Brown, Dana-Farber Cancer
Institute, Dr. Ian Flinn, Sarah Cannon Research Institute, Dr.
Steven Horwitz, Memorial Sloan Kettering Cancer Center as well as
Dr. Brian Koffman, Founder & Medical Director of the Chronic
Lymphocytic Leukemia (CLL) Society, and a CLL patient, joined the
Verastem Oncology executive leadership team for an in-depth
discussion regarding the unmet need among CLL/SLL and FL patients,
where PI3K-delta and PI3K-gamma inhibitors fit into the treatment
paradigm, and the growing opportunity for duvelisib in CLL/SLL and
FL, and beyond. The Company also provided an overview of its
duvelisib commercial strategy and initiatives. The webcast is
available within the “Media” section of the Company’s website at
www.verastem.com.
- Signed exclusive license agreement
with Yakult Honsha Co., Ltd. (Yakult) to develop and commercialize
duvelisib in Japan – In June 2018, Verastem Oncology announced
its entry into an exclusive license and collaboration agreement
with Yakult to develop and commercialize duvelisib for the
treatment, prevention or diagnosis of all oncology indications in
Japan. The transaction, which carries a total deal value of up to
$100.0 million, includes a one-time upfront payment of $10.0
million and up to an additional $90.0 million if certain future
pre-specified development, regulatory and commercial milestones are
successfully achieved by Yakult. In addition, Verastem Oncology is
also eligible to receive double-digit royalties based on future net
sales of duvelisib in Japan. Pursuant to the agreement, Yakult has
the right to develop and commercialize duvelisib in Japan at its
own cost and expense. In addition, Yakult may fund certain global
development costs on a pro-rata basis. Verastem Oncology retains
all rights to duvelisib outside of Japan.
- Strengthened the balance sheet
through the sale of equity for net proceeds of approximately $105
Million – In May 2018, Verastem Oncology completed an
underwritten registered offering of 8,944,444 shares of its common
stock at a price to the public of $4.50 per share. The net proceeds
to Verastem from the offering were approximately $38.3 million. In
June 2018, Verastem Oncology completed a registered offering of
7,166,666 shares of its common stock at a price of $6.00 per share
to funds managed by Consonance Capital. The net proceeds to
Verastem Oncology from this offering were approximately $42.8
million. The Company also sold 6,314,410 shares of common stock
under its at-the-market equity offering program for net proceeds of
approximately $23.7 million.
- Joined the Russell 3000® Index –
In June 2018, the Company joined the broad-market Russell 3000®
Index as part of the Russell US Indexes annual reconstitution.
Scientific Presentations at Major Medical Meetings
Duvelisib
- The efficacy of duvelisib
monotherapy following disease progression on ofatumumab monotherapy
in patients with relapsed/refractory CLL or SLL in the DUO™
crossover extension study – In June 2018, at both the American
Society of Clinical Oncology 2018 Annual Meeting (ASCO 2018) and
the European Hematology Association 2018 Annual Meeting (EHA 2018),
Dr. Byrone Kuss, Flinders Medical Centre, and Dr. Peter Hillman,
St. James University Hospital, respectively, presented additional
data from the open-label, DUO crossover extension study where
patients with radiologically confirmed progressive disease (PD)
following treatment with ofatumumab in DUO were given the option to
receive treatment with duvelisib. Among the 89 evaluable patients
(median 3 prior therapies; range 2-8), duvelisib as a monotherapy
achieved a 73% overall response rate (ORR) per investigators
assessment in the extension study (95% confidence interval CI:
64,82); 5% complete response with incomplete marrow recovery (CRi),
and 68% partial response (PR). The median progression-free survival
(mPFS) for duvelisib in the DUO crossover extension study was 15
months (95% CI: 10,17). Notably, 83% of patients in the duvelisib
arm post-crossover had >50% reductions in the size of their
target nodal lesions. The safety profile of duvelisib as a
monotherapy was manageable and consistent with what was observed in
the Phase 3 DUO™ study. These data build upon the previously
reported positive DUO results and further support duvelisib as an
effective oral monotherapy treatment option for patients with
relapsed or refractory CLL/SLL.
- A Phase IB/II study of duvelisib in
combination with Fludarabine (F), Cyclophosphamide (C), and
Rituximab (R) (dFCR) for frontline therapy of younger CLL
patients – At EHA 2018, Dr. Matthew Davids, Dana-Farber Cancer
Institute, presented data on the 31 patients evaluable for
post-dFCR response. The ORR was 94%, with 26% (n=8) of patients
achieving a complete response (CR) or CRi, and 68% achieving a PR.
The best rate of minimum residual disease (MRD) negativity in the
bone marrow (BM) in patients with at least one evaluation was 76%
(22 of 29 patients). All patients who achieved CR/CRi at the
primary endpoint also had BM-MRD negativity (26%). Among survivors,
the median follow-up is 24.5 months (range 6.9-46 months). The
two-year progression-free survival and overall survival rates for
patients in the study were both 97%. Eight patients have now
completed two years of duvelisib maintenance therapy. Based on
these results the recommended Phase 2 dose of duvelisib in
combination with FCR was 25mg twice daily. The most common all
grade non-hematologic adverse events (AEs) were nausea (72%, all
Grade 1/2), fatigue (69%, 3% Grade 3), fever (53%, all Grade 1/2),
diarrhea (47%, 3% Grade 3), transaminitis (34%, 28% Grade 3/4),
anorexia (34%, all Grade 1/2), vomiting (28%, all Grade 1/2),
pruritus (16%, 3% Grade 3), arthritis (9%, all Grade 2) and
Cytomegalovirus (CMV) reactivation (6%, both Grade 2). The most
common all grade hematologic adverse events were thrombocytopenia
(65%; 34% Grade 3-4), neutropenia (59%; 50% Grade 3-4), and anemia
(38%, 16% Grade 3). Serious AEs included transaminitis (Grade ≥3),
febrile neutropenia (n=6, all Grade 3), pneumonia (n=6, including 3
cases of PJP despite planned prophylaxis), and colitis (n=1 Grade
2, n=1 Grade 3). These results suggest that duvelisib in
combination with FCR is an effective regimen for the initial
therapy of younger, fit CLL patients and results in a high rate of
BM-MRD negativity (76%), significantly higher than historical data
with FCR.
- The effect of duvelisib, a dual
inhibitor of PI3K-δ,γ, on components of the tumor microenvironment
in previously untreated follicular lymphoma patients – At both
ASCO 2018 and EHA 2018, Dr. Carla Casulo, University of Rochester,
Wilmot Cancer Center, presented data from blood samples from
healthy volunteers and FL patients treated in the CONTEMPO study.
Samples collected both pre- and post-duvelisib treatment were
analyzed. Ex vivo and in vitro PI3K-delta assays and PI3K-gamma
assays, with PI3K-gamma-selective (idelalisib, TGR-1202, IPI-3063)
and PI3K-delta-selective (IPI-549) inhibitors were compared.
Collectively, the results of this analysis support the thesis that
duvelisib disrupts PI3K-delta and PI3K-gamma function in FL
patients, inhibiting the tumor microenvironment (TME)
cancer-supportive macrophages and T-cells.
- Duvelisib inhibition of chemokines
in patients with CLL (DUO™) and iNHL (DYNAMO™) – At both
ASCO 2018 and EHA 2018, Dr. David Weaver, Verastem Oncology’s Vice
President, Translational Medicine, presented data showing that
PI3K-delta inhibition directly targets proliferation and survival
of malignant leukemia and lymphoma cells, while PI3K-gamma
inhibition modulates the TME through key support cells, including
tumor-associated macrophages, nurse-like stroma and T-cells, and
via soluble factors stimulating tumor growth, survival and
migration. Serum samples from patients in the Phase 3 DUO study in
relapsed/refractory CLL/SLL and the Phase 2 DYNAMO study in
relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) were
collected at baseline and at infusion cycle date C2D1 and used for
correlative studies of 24 chemokines, cytokines and serum factors.
These data support the hypothesis that treatment with duvelisib
results in significant reduction of chemokines potentially derived
from the tumor cells and TME and that further investigation of the
effects of duvelisib on TME pharmacodynamic markers is
warranted.
- Presented scientific data supporting
immuno-oncology applications of duvelisib at the 3rd annual
Advances in Immuno-Oncology Congress – In May 2018, Jonathan
Pachter, Ph.D., Verastem Oncology’s Chief Scientific Officer, gave
an oral presentation highlighting the unique potential of
duvelisib, as a dual inhibitor of PI3K-delta and PI3K-gamma, to
enhance the efficacy of immune checkpoint and co-stimulatory
antibodies in preclinical models of both hematological malignancies
and solid tumors. Dr. Pachter also moderated a round table
discussion regarding novel checkpoint pathways and emerging
strategies for combined modality treatment.
Defactinib
- Presented preliminary Phase 1
results from combination trial with defactinib, pembrolizumab and
gemcitabine in advanced cancer – At ASCO 2018, Dr.
Andrea Wang-Gillam presented a poster describing results from the
ongoing Phase 1 study evaluating defactinib in combination with
pembrolizumab and gemcitabine in patients with advanced cancer,
including pancreatic cancer. The combination treatment appears to
be well tolerated, the recommended Phase 2 dose was established,
and the expansion phase of the study is now ongoing. Encouraging
signs of clinical activity were observed in three pancreatic ductal
adenocarcinoma (PDAC) patients treated beyond 250 days, including
one patient with confirmed PR and two patients with stable disease.
Meaningful reductions (57-96%) in the pancreatic cancer marker
CA19-9 were also observed in all three patients. In addition,
analysis of paired biopsies showed that the combination treatment
induced desirable biomarker changes including increased
proliferating CD8+ T-cells and reduced immunosuppressive Tregs and
macrophages.
- Presented scientific data supporting
immuno-oncology applications of defactinib at the 3rd Annual
Advances in Immuno-Oncology Congress – During Dr.
Pachter’s oral presentation, he also provided an update on the
scientific rationale and clinical progress of Verastem Oncology’s
lead focal adhesion kinase (FAK) inhibitor, defactinib, in
combination with PD-1 and PD-L1 inhibitors in solid tumors.
All posters and presentations are available within the “Media”
section of the Company’s website at www.verastem.com.
Second Quarter 2018 Financial Results
Net loss for the three months ended June 30, 2018 (2018 Quarter)
was $18.4 million, or $0.30 per share, as compared to a net loss of
$13.4 million, or $0.36 per share, for the three months ended June
30, 2017 (2017 Quarter). Net loss for the 2018 Quarter includes
license revenue of $10.0 million, related to the upfront payment
received in connection with the license and collaboration agreement
with Yakult in June 2018. Cash used in operating activities,
excluding the upfront payment from Yakult, was $20.3 million for
the 2018 Quarter.
Research and development expense for the 2018 Quarter was $12.4
million compared to $9.0 million for the 2017 Quarter. The $3.4
million increase from the 2017 Quarter to the 2018 Quarter was
primarily related to an increase of $1.6 million in contract
research organization expense for outsourced biology, development
and clinical services, which includes the Company’s clinical trial
costs, an increase of $1.0 million in personnel related costs, and
an increase of $0.4 million in stock-based compensation
expense.
General and administrative expense for the 2018 Quarter was
$15.8 million compared to $4.4 million for the 2017 Quarter. The
increase of $11.4 million from the 2017 Quarter to the 2018 Quarter
primarily resulted from increases in consulting and professional
fees of $5.2 million, including $3.6 million related to commercial
launch preparation activities, and an increase in personnel related
costs of $4.4 million.
As of June 30, 2018, Verastem Oncology had cash and cash
equivalents of $168.7 million compared to $86.7 million of cash,
cash equivalents and investments as of December 31, 2017.
The number of outstanding common shares as of June 30, 2018 was
73,579,699.
Financial Guidance
Based on the Company’s current operating plans, assuming a
favorable regulatory decision and estimated revenue, it expects to
have sufficient cash and cash equivalents to fund operations into
2020.
About Duvelisib
Duvelisib is a first-in-class investigational oral, dual
inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma,
two enzymes known to help support the growth and survival of
malignant B-cells and T-cells. PI3K signaling may lead to the
proliferation of malignant B- and T-cells and is thought to play a
role in the formation and maintenance of the supportive tumor
microenvironment.1,2,3 Duvelisib was evaluated in late- and
mid-stage extension trials, including DUO™, a randomized, Phase 3
monotherapy study in patients with relapsed or refractory chronic
lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL),4 and DYNAMO™, a single-arm, Phase 2 monotherapy
study in patients with refractory indolent non-Hodgkin lymphoma
(iNHL).5 Both DUO and DYNAMO achieved their primary endpoints.
Verastem Oncology’s New Drug Application (NDA) requesting the full
approval of duvelisib for the treatment of patients with relapsed
or refractory CLL/SLL, and accelerated approval for the treatment
of patients with relapsed or refractory follicular lymphoma (FL)
was accepted for filing by the U.S. Food and Drug
Administration (FDA), granted Priority Review and assigned a
target action date of October 5, 2018. Duvelisib is also being
developed by Verastem Oncology for the treatment of peripheral
T-cell lymphoma (PTCL), and is being investigated in combination
with other agents through investigator-sponsored
studies.6 Information about duvelisib clinical trials can be
found on www.clinicaltrials.gov.
About Defactinib
Defactinib is an investigational inhibitor of focal adhesion
kinase (FAK), a non-receptor tyrosine kinase that mediates
oncogenic signaling in response to cellular adhesion and growth
factors.7 Based on the multi-faceted roles of FAK, defactinib
is used to treat cancer through modulation of the tumor
microenvironment and enhancement of anti-tumor
immunity.8,9 Defactinib is currently being evaluated in three
separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different
cancer types including pancreatic cancer, ovarian cancer, non-small
cell lung cancer (NSCLC), and mesothelioma. These studies are
combination clinical trials with pembrolizumab and avelumab
from Merck & Co. and Pfizer/Merck KGaA,
respectively.10,11,12 Information about these and additional
clinical trials evaluating the safety and efficacy of defactinib
can be found on www.clinicaltrials.gov.
About Verastem Oncology
Verastem, Inc. (Nasdaq:VSTM), operating as Verastem
Oncology, is a biopharmaceutical company focused on developing and
commercializing medicines to improve the survival and quality of
life of cancer patients. Verastem Oncology is currently developing
duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has
successfully met its primary endpoint in a Phase 2 study in
indolent non-Hodgkin lymphoma and a Phase 3 clinical trial in
patients with chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL). Verastem Oncology’s New Drug Application (NDA)
requesting the full approval of duvelisib for the treatment of
patients with relapsed or refractory CLL/SLL, and accelerated
approval for the treatment of patients with relapsed or refractory
follicular lymphoma (FL) was accepted for filing by the U.S.
Food and Drug Administration, granted Priority Review and assigned
a target action date of October 5, 2018. In addition, Verastem
Oncology is developing the focal adhesion kinase (FAK) inhibitor
defactinib, which is currently being evaluated in three separate
clinical collaborations in combination with immunotherapeutic
agents for the treatment of several different cancer types,
including pancreatic cancer, ovarian cancer, non-small cell lung
cancer (NSCLC), and mesothelioma. Verastem Oncology’s
product candidates seek to treat cancer by modulating the local
tumor microenvironment and enhancing anti-tumor immunity. For more
information, please visit www.verastem.com.
Forward-looking statements notice:
This press release includes forward-looking statements about
Verastem Oncology’s strategy, future plans and prospects, including
statements regarding Verastem Oncology’s future financial position,
objectives of management, the development and activity of Verastem
Oncology’s investigational product candidates, including duvelisib
and defactinib, and Verastem Oncology’s PI3K and FAK programs
generally, the structure of its planned and pending clinical
trials, Verastem Oncology’s financial guidance and the timeline and
indications for clinical development, regulatory submissions and
commercialization activities. The words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statement. Applicable risks and
uncertainties include the risks that approval of Verastem
Oncology’s New Drug Application for duvelisib will not occur on the
expected timeframe or at all, including by the U.S. Food and Drug
Administration’s target action date; that even if data from
clinical trials is positive, regulatory authorities may require
additional studies for approval and the product may not prove to be
safe and effective; that the preclinical testing of Verastem
Oncology’s product candidates and preliminary or interim data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials; that a filing of a European
Marketing Authorization Application may not be achieved; that the
full data from the DUO™ study will not be consistent with the
previously presented results of the study; that data may not be
available when expected, including for the Phase 3 DUO study; that
the degree of market acceptance of product candidates, if approved,
may be lower than expected; that the timing, scope and rate of
reimbursement for Verastem Oncology’s product candidates is
uncertain; that there may be competitive developments affecting its
product candidates; that data may not be available when expected;
that enrollment of clinical trials may take longer than expected;
that Verastem Oncology’s product candidates will cause unexpected
safety events or result in an unmanageable safety profile as
compared to their level of efficacy; that duvelisib will be
ineffective at treating patients with lymphoid malignancies; that
Verastem Oncology will be unable to successfully initiate or
complete the clinical development and eventual commercialization of
its product candidates; that the development and commercialization
of Verastem Oncology’s product candidates will take longer or cost
more than planned; that Verastem Oncology may not have sufficient
cash to fund its contemplated operations; that Verastem Oncology or
Infinity Pharmaceuticals, Inc. will fail to fully perform under the
duvelisib license agreement; that Verastem Oncology may be unable
to make additional draws under its debt facility or obtain adequate
financing in the future through product licensing, co-promotional
arrangements, public or private equity, debt financing or
otherwise; that Verastem Oncology will not pursue or submit
regulatory filings for its product candidates, including for
duvelisib in patients with CLL/SLL or iNHL; and that Verastem
Oncology’s product candidates will not receive regulatory approval,
become commercially successful products, or result in new treatment
options being offered to patients. Other risks and uncertainties
include those identified under the heading "Risk Factors" in the
Company’s Quarterly Report on Form 10-Q for the quarterly period
ended June 30, 2018, its Annual Report on Form 10-K for the year
ended December 31, 2017 as filed with the Securities and Exchange
Commission (SEC) on March 13, 2018 and in any subsequent filings
with the SEC. The forward-looking statements contained in this
press release reflect Verastem Oncology’s views as of the date
hereof, and the Company does not assume and specifically disclaims
any obligation to update any forward-looking statements whether as
a result of new information, future events or otherwise, except as
required by law.
References
1 Winkler D.G., Faia K.L., DiNitto J.P. et al. PI3K-delta and
PI3K-gamma inhibition by IPI-145 abrogates immune responses and
suppresses activity in autoimmune and inflammatory disease models.
Chem Biol 2013; 20:1-11. 2 Reif K et al. Cutting Edge: Differential
Roles for Phosphoinositide 3 kinases, p110-gamma and p110-delta, in
lymphocyte chemotaxis and homing. J Immunol 2004:173:2236-2240. 3
Schmid M et al. Receptor Tyrosine Kinases and TLR/IL1Rs
Unexpectedly activate myeloid cell PI3K, a single convergent point
promoting tumor inflammation and progression. Cancer Cell
2011;19:715-727.
4 www.clinicaltrials.gov, NCT02004522
5 www.clinicaltrials.gov, NCT01882803
6 www.clinicaltrials.gov, NCT02783625,
NCT02158091
7 Schaller M.D. and Parsons J.T. Focal adhesion kinase: an
integrin-linked protein tyrosine kinase. Trends Cell Biol. 1993 3:
258-62. 8 Jiang H et al. Targeting focal adhesion kinase renders
pancreatic cancers responsive to checkpoint immunotherapy. Nat Med
2016: Aug 22(8) 851-60. 9 Sulzmaier F.J. et al. FAK in cancer:
mechanistic findings and clinical applications. Nature Rev Cancer.
2014 14: 598-610.
10 www.clinicaltrials.gov, NCT02546531
11 www.clinicaltrials.gov, NCT02943317
12 www.clinicaltrials.gov, NCT02758587
Verastem, Inc.
Condensed Consolidated Balance
Sheets
(in thousands)
June 30, December
31, 2018 2017 (unaudited) Cash, cash
equivalents and investments $ 168,692 $ 86,672 Prepaid expenses and
other current assets 1,745 1,115 Property and equipment, net 1,270
861 Other assets 1,211 1,143
Total assets
$ 172,918 $ 89,791 Accounts
payable, accrued expenses and other current liabilities $ 22,132 $
17,128 Long-term debt 23,520 14,828 Other liabilities 399 151
Stockholders’ equity 126,867 57,684
Total
liabilities and stockholders’ equity $ 172,918
$ 89,791
Verastem, Inc.
Unaudited Condensed Consolidated
Statements of Operations
(in thousands, except per share
amounts)
Three months ended June 30,
Six months ended June 30, 2018 2017
2018 2017 Revenue: License revenue $ 10,000 $
— $ 10,000 $ — Total revenue 10,000
— 10,000 —
Operating expenses: Research and development 12,381 9,042 23,315
17,427 General and administrative 15,813 4,425
25,640 9,188 Total operating
expenses 28,194 13,467 48,955
26,615 Loss from operations (18,194 )
(13,467 ) (38,955 ) (26,615 ) Interest income
343 140 534 295 Interest expense (516 ) (109 )
(996 ) (121 )
Net loss $ (18,367
) $ (13,436 ) $ (39,417
) $ (26,441 ) Net loss per
share—basic and diluted $ (0.30 ) $
(0.36 ) $ (0.70 ) $
(0.71 ) Weighted-average number of common shares
used in net loss per share-basic and diluted
61,256 36,992
56,074 36,992
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180808005717/en/
Verastem OncologyMarianne M. LambertsonVice President,
Corporate CommunicationsInvestor Relations/Public Relations+1
781-292-4273mlambertson@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024